Literature DB >> 7575660

The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma.

N M Gray1, C L Marr, C R Penn, J M Cameron, R C Bethell.   

Abstract

(-)-2'-deoxy-3'-thiacytidine (3TC) has been shown to be a potent, selective inhibitor of HIV replication in vitro, which requires phosphorylation to its 5'-triphosphate for antiviral activity. The intracellular concentration of 3TC 5'-triphosphate in phytohaemagglutinin (PHA)-stimulated peripheral blood lymphocytes (PBL) shows a linear dependence on the extracellular concentration of 3TC up to an extracellular 3TC concentration of 10 microM. At this extracellular concentration of 3TC, the resulting intracellular concentration of 3TC 5'-triphosphate is 5 microM. This value is similar to the inhibition constant (Ki) values for the competitive inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and human DNA polymerases (10-16 microM) by 3TC 5'-triphosphate. Since the concentration of 3TC producing 90% inhibition (IC90) of HIV replication in PBLs has been reported to be 76 nM, the antiviral activity of 3TC requires intracellular concentrations of 3TC 5'-triphosphate, which would result in very little inhibition of reverse transcriptase if its sole mode of action was competitive inhibition. This apparent discrepency may be explained by the ability of 3TC 5'-triphosphate to act as a substrate for reverse transcriptase. Primer extension assays have shown that 3TC 5'-triphosphate is a substrate for HIV-1 reverse transcriptase and DNA polymerase gamma, resulting in the incorporation of 3TC 5'-monophosphate into DNA. In the case of DNA polymerase gamma, the product of this reaction (i.e. double-stranded DNA with 3TC 5'-monophosphate incorporated at the 3'-terminus of the primer strand) is also a substrate for the 3'-5' exonuclease activity of this enzyme. This may explain the low levels of mitochondrial toxicity observed with 3TC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575660     DOI: 10.1016/0006-2952(95)96620-a

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  19 in total

1.  Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  Stephen Kewn; Patrick G Hoggard; Sean D Sales; Kevin Jones; Bridget Maher; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.

Authors:  X R Pan-Zhou; L Cui; X J Zhou; J P Sommadossi; V M Darley-Usmar
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 4.  Mitochondrial toxicity and HIV therapy.

Authors:  A J White
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

Review 5.  A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.

Authors:  Karen S Anderson
Journal:  Methods       Date:  2010-05-31       Impact factor: 3.608

Review 6.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

7.  Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors:  Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 8.  Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

9.  Inhibition of guanosine monophosphate synthetase by the substrate enantiomer L-XMP.

Authors:  Nicholas B Struntz; Tianshun Hu; Brian R White; Margaret E Olson; Daniel A Harki
Journal:  Chembiochem       Date:  2012-10-23       Impact factor: 3.164

10.  Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.

Authors:  Jeremiah W Hanes; Kenneth A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.